Danish pharmaceutical major Novo Nordisk, on Monday, said it would soon launch its insulin injection Tresiba (insulin degludec) in India.
Novo Nordisk is the leading manufacturer of insulin in the world, and Tresiba, the new basal insulin, is used for the treatment of Type 1 and Type 2 diabetes.
The once-daily use medicine has a duration of action beyond 42 hours, and allows flexibility in daily dosing time without reducing efficacy , Melvin D’Souza, Managing Director, Novo Nordisk India, said, while addressing a media conference here. “Tresiba will be launched towards the end of the year, and the price of the product will be announced closer to the launch date,” he said.
Novo Nordisk India has 15 per cent share in the diabetes care market with a significant share in insulin, and is hopeful of growing at 15 per cent per annum, Mr. D’Souza added. Tresiba will be made available in FlexTouch, a pre-filled pen with an easy touch button, enabling doses of up to 80 units in a single injection.
Novo Nordisk ties up with IAD
In a bid to provide doctors access to updated and scientific information on insulin therapy, Novo Nordisk has tied up with Indian Academy of Diabetes (IAD) to launch a massive doctor education programme – Master Class in Insulin.
India has 65 million diabetes patients and 130 million pre-diabetes patients, said Dr. Shashank Joshi, President, IAD. “Yet, only 6 million receive appropriate treatment.
The programme will use the peer-to-peer model where the focus will be on engaging national leaders who are pioneers in ‘insulinology’ and ‘diabetology’, and these doctors will further train 1,000 primary care physicians across the country.”
